CML publications

Please find below a selection of interesting articles on CML from peer-reviewed journals. Recent publications include:

Clinical papers

Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
Padala S and Cortes J. Haematologica, April 2023 (epub ahead of print)
– open access publication
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal
Pavlovsky C et al. J Hematol Oncol, April 2023 – open access publication
Cardiovascular risk in chronic myeloid leukemia: A multidisplinary consensus on screening and management
Milojkovic D et al. Eur J Haematol, April 2023 (epub ahead of print) – open access publication
Gene expression pattern of ESPL1, PTTG1 and PTTG1IP can potentially predict response to TKI first-line treatment of patients newly diagnosed CML
Christiani E et al. Cancers(Basel), May 2023 – open access publication
A pragmatic approach to managing long-term adverse effects in chronic myeloid leukemia treatment - Review
Lucero JA and Lipton JH. Curr Hematol Malig Rep, May 2023 (epub ahead of print)
The importance of developing open communication and a professional, long-term relationship between patients with chronic myeloid leukemia and their oncologist - Review
Clements J et al. Future Oncol, May 2023 (epub ahead of print) – open access publication
SOHO state of the art updates and next questions / Update on treatment-free-remission in chronic myeloid leukemia (CML) - Review
Mikhaeel S and Atallah E. Clin Lymphoma Myeloma Leuk, May 2023
Imatinib compared to second-generation tyrosine kinase inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase
Yang S et al. Am J Hematol, May 2023 (epub ahead of print) – open access publication
Response-based dosing for ponatinib: Model-based analyses of the dose-ranging OPTIC study
Hanley MJ et al. Clin Pharmacol Ther, May 2023 (epub ahead of print)
Chronic Myeloid Leukemia following Exposure to Radioactive Iodine (I131): A Systematic Review
Ali Hailan YM et al. Oncology, May 2023 – open access publication
A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
Kaddoura R et al. Front Med, May 2023 – open access publication

Scientific papers

Modeling global genomic instability in chronic myeloid leukemia (CML) using patient-derived induced pluripotent stem cells (iPSCs)
Telliam G et al. Cancers(Basel), May 2023 – open access publication
Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
Langhammer M et al. Leukemia, May 2023 (epub ahead of print) – open access publication
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Hiroshi H et al. Sci Rep, May 2023 – open access publication
Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells
Qiu S et al. Blood, May 2023 (epub ahead of print)

More CML Publications 2023

Clinical Publications	Scientific Publications
May 2023
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplant - Review Uhm J. Blood Res, April 2023 - open access publication	Frequency and driver mutation diversity in concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm Langabeer SE et al. Int J Hematol, April 2023 (epub ahead of print)
Developing therapeutic approaches for CML: a review Kumar V et al. Mol Cell Biochem, May 2023	Differentiation of imatinib-resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A. Xu Y et al. Cancer, May 2023 – open access publication
The EMA assessment of Asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who were previously treated with at least two tyrosine kinase inhibitors Tesileanu CMS et al. Oncologist, May 2023 (epub ahead of print) – open access publication	I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition Gao C et al. Front Pharmacol, April 2023 – open access publication
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase focusing on age and dose effects Tokuhira M et al. Int J Hematol, May 2023 (epub ahead of print)	Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells Mitrovsky O et al. PLoSOne, May 2023 – open access publication
Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted! Eskazan AE et al. Cancer, May 2023 (epub ahead of print)
JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response Tossoni L et al. Ann Hematol, May 2023
April 2023
The outcome of post-transplant asciminib in patients with CML Fernando F et al. Bone Marrow Transplant, April 2023 (epub ahead of print)	New patterns of genetic instability in chronic myelogenous leukemia: interesting, but not ready for clinical use Schiffer CA. Haematologica, April 2023 (epub ahead of print) – open access publion
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial Réa D et al. Leukemia, April 2023 (epub ahead of print) – open access publication	The structure of the hematopoietic system can explain chronic myeloid leukemia progression Pérez-Jiménez M et al. Sci Rep, April 2023 – open access publication
Management of chronic myeloid leukemia in 2023 – Common ground and common sense - Review Senapati J et al. Blood Cancer J, April 2023 – open access publication	Characterization of bone marrow niche in chronic myeloid leukemia patients identifies CXCL14 as a new therapeutic option Polinska M et al. Blood, April 2023 (epub ahead of print)
Efficacy and safety of nilotinib in chronic myeloid leukemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study Dulucq S et al. Br J Haematol, April 2023 (epub ahead of print) – open access publication	IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia Fiordi B et al. Haematologica, April 2023 (epub ahead of print) – open access publication
Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event Tarantini F et al. Leuk Res, April 2023	Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia Zhong FM et al. Cancer Cell Int, April 2023 – open access publication
Managing women of childbearing age with chronic myeloid leukemia: Safety and treatment considerations Expert Rev Hematol, April 2023 (epub ahead of print)	Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia Zhong FM et al. Cancer Cell Int, April 2023 – open access publication
An analysis of dasatinib treatment patterns in patients with chronic myeloid leukemia after experiencing pleural effusion during dasatinib therapy McBride A et al. Acta Haematol, April 2023 (epub ahead of print)
Efficacy and safety of nilotinib as frontline therapy in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials Luciano L et al. Ann Hematol, April 2023 (epub ahead of print) – open access publication
Applications of machine learning in chronic myeloid leukemia - Review Elhadary M et al. Diagnostics(Basel), April 2023 – open access publication
Breaking the mold: asciminib as a standard of care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting Yilmaz R et al. Future Oncol, April 2023 (epub ahead of print)
Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia – Review Han JJ et al. Blood Res, April 2023 (epub ahead of print) – open access publication
Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings - Review Cheng F et al. Front Oncol, April 2023 – open access publication
Assessment of imatinib as a primary treatment of chronic myeloid leukemia in chronic phase: a Cohort Study Merin D et al. J Oncol Pharm Pract, April 2023
March 2023
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL Hochhaus A et al. Leukemia, March 2023 – open access publication	AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells Lee YC et al. Biochem Pharmacol, March 2023
A sciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results Mauro MJ et al. Leukemia, March 2023 (epub ahead of print) – open access publication	The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere lengths in chronic myeloid leukemia Deregowska A et al. J Cancer Res Clin Oncol, March 2023 (epub ahead of print) – open access publication
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention Shanmunagathan N et al. Haematologica, March 2023 (epub ahead of print) – open access publication	Induction of DNMT1-dependent demethylation of SHP-1 by the natural flavonoid compound Baicalein overcame imatinib-resistance in CML CD34+ cells Xu X et al. Cell Commun Signal, March 2023 – open access publication
Editorial: Advances in the treatment of chronic myeloid leukemia Eskazan AE et al. Front Oncol, March 2023 – open access publication	Imatinib blocks tyrosine phosphorylation of Smad4 and restores TFG-ß growth-suppressive signaling in BCR-ABL1-positive leukemia Wang L et al. Signal Transduct Target Ther, March 2023 – open access publication
High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population Kockerols CCB et al. Haematologica, March 2023 (epub ahead of print) – open access publication	The prognostic and therapeutic potential of HO-1 in leukemia and MDS – Review Sadeghi M et al. Cell Commun Signal, March 2023 – open access publication
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence Shallis RM et al. Blood Adv, March 2023 (epub ahead of print) – open access publication	NOX2 and NOX4 control mitochondrial function in chronic myeloid leukemia Romo-González M et al. Free Radic Biol Med, March 2023 – open access publication
The economic burden of chronic myeloid leukemia in patients with later lines: Findings from a real-world analysis in Italy Breccia M et al. Adv Ther, March 2023 – open access publication	TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN Qiu Q et al. Signal Transduct Target Ther, March 2023 – open access publication
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia Krishnan V et al. Blood, March 2023 (epub ahead of print)	Molecular mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia Kaehler M and Cascorti I. Handb Exp Pharmacol, March 2023 (epub ahead of print)
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian Medicines Agency (AIFA) Breccia M et al. Ann Hematol, March 2023 (epub ahead of print)
Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm Walia A and Prasad V. Blood Cancer J, March 2023 – open access publication
Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia Aleem A et al. Int J Hematol, March 2023 (epub ahead of print)
Association between bariatric surgery and outcomes in chronic myeloid leukemia Haddad FG et al. Cancer, March 2023 (epub ahead of print)
Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase – Review Choi EJ. Blood Res, March 2023 (epub ahead of print) – open access publication
Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia (RODEO study): study protocol for prospective, multicentre, single-arm trial Djodikromo MF et a. BMC Cancer, March 2023 – open access publication
February 2023
Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells Tsubaki M et al. BMB Rep, February 2023 – open access publication	Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for the novo lymphoid blast phase-chronic myeloid leukemia Yang Z et al. Leuk Res, February 2023 (epub ahead of print)
Repurposing the Bis-Biguanide Alexidine in combination with tyrosine kinase inhibitors to eliminate leukemic stem/progenitor cells in chronic myeloid leukemia Muselli F et al. Cancers(Basel), February 2023 – open access publication	Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: characteristics, potential mechanism, and clinical management strategies – Review Cheng F et al. Front Oncol, February 2023 – open access publication
Discovery of CZS-241: A potent, selective, and orally available Polo-like kinase 4 inhibitor for the treatment of CML Sun Y et al. J Med Chem, February 2023	Cardiovascular toxicities associated with tyrosine kinase inhibitors - Review Sahegh N et al. Curr Cardiol Rep, February 2023 (epub ahead of print)
Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia Jiang B et al. Front Oncol, February 2023 – open access publication	The bone marrow immune environment in CML: Treatment responses, treatment-free remission and therapeutic vulnerabilities Patterson SD & Copland M. Curr Hematol Malig Rep, February 2023 (epub ahead of print) – open access publication
A survey of patient experience in CML: American and Canadian Perspectives Hillis C et al. Patient Prefer Adherence, February 2023 – open access publication
Importance of tyrosine kinase inhibitor treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-Free study Yoshida C et al. Int J Hematol, February 2023 (epub ahead of print) – open access publication
Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network Nunes RAB et al. Front Cardiovasc Med, February 2023 – open access publication
Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison Hyland KA et al. Leuk Lymphoma, February 2023
Family planning and pregnancy in patients with chronic myeloid leukemia – Review Berman E et al. Curr Hematol Malig Rep, February 2023 (epub ahead of print)
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modelling and pathway analysis Radich JP et al. Haematologica, February 2023 (epub ahead of print) – open access publication
January 2023
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in CML Irani YD et al. Blood Adv, January 2023 (epub ahead of print) – open access publication	Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL Hochhaus A et a. Leukemia, January 2023 (epub ahead of print) – open access publication
RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia Zhang H et al. Haematologica, January 2023 – open access publication	Matching adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors Atallah E et al. J Caner Res Clin Oncol, January 2023 (epub ahead of print) – open access publication
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib Häselbarth L et al. Cancer Immunol Immunother, January 2023 (epub ahead of print) – open access publication	Allogeneic transplantation for chronic myeloid leukemia: I’m not dead yet! Radich J. Am J Hematol, January 2023 – open access publication
mTORC2 is activated under hypoxia and could support chronic myeloid leukemia stem cells Panuzzo C et al. Int J Mol Sci, January 2023 – open access publication	Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor Bidikian A et al. Am J Hematol (epub ahead of print)
BH3 mimetics and TKI combined therapy for CML Brumatti G et al. Biochem, January 2023 – open access publication	The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors Jabbour EJ et al. Am J Hematol, January 2023 (epub ahead of print)
Differential inhibition of T cell receptor and STAT5 signalling pathways determine the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia Harrington P et al. Haematologica, January 2023 (epub ahead of print) – open access publication	A systematic review on second treatment-free remission (TFR) attempt in chronic myeloid leukemia (CML): Can it be applied in clinical practice? - Review Çiftçiler R et al. Clin Lymphoma Myeloma Leuk (epub ahead of print)
	Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring Bataller A et al. Leuk Lymphoma, January 2023 (epub ahead of print)
	Is it time to reconsider molecular response milestones in CML? Walia A and Prasad V. Am J Hematol, January 2023 (epub ahead of print)